Skip to main content

Table 4 Reported adverse events (side effects)

From: Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial

 

Site 1

Site 2

AL (N = 175)

AQAS (N = 172)

p-value*

AL (N = 165)

AQAS (N = 168)

p-value*

Any adverse event

 Caregiver reported

6 (3.4%)

27 (15.7%)

< 0.001

25 (15.2%)

41 (24.4%)

0.039

Specific adverse events

 Vomiting

4 (2.3%)

16 (9.3%)

0.005

13 (7.9%)

18 (10.7%)

0.452

 Weakness-Fatigue

0 (0.0%)

12 (7.0%)

< 0.001

9 (5.5%)

29 (17.3%)

0.001

 Dizziness

0 (0.0%)

10 (5.8%)

0.001

7 (4.2%)

4 (2.4%)

0.376

 Diarrhoea

1 (0.6%)

3 (1.7%)

0.369

2 (1.2%)

2 (1.2%)

1.000

 Other gastrointestinal complaintsa

1 (0.6%)

5 (2.9%)

0.119

2 (1.2%)

4 (2.4%)

0.685

 Other AE reportedb

1 (0.6%)

2 (1.2%)

0.621

4 (2.4%)

4 (2.4%)

1.000

  1. * Fisher’s exact test
  2. aReported one or more of the following: diarrhoea, anorexia, nausea or abdominal pain
  3. b Other AE’s reported: Site 1— AL: 1 pruritic; AQAS: 1 headache & 1 not specified. Site 2—AL: 2 change in urine colour, 1 cold/flu, & 1 sweating; AQAS: 1 change in urine colour, 1 fever, 1 mouth sores & 1 unspecified